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Aloe emodin, an anthraquinone exhibits higher cytotoxicity to hepatoma, 
prostate and cervical cancer cells through cell cycle arrest and apoptosis 
compared to normal cells. However, its underlying mechanism on ER+-
breast cancer cell death remains unclear. Therefore, this study was done to 
investigate aloe emodin cytotoxicity and its mechanism on estrogen receptor 
(ER)-positive (MCF-7), ER-negative breast cancer cells (MDA-MB-231) and 
control breast cells (MCF-10A) in comparison with tamoxifen. Cytotoxicity 
was determined using WST-1 proliferation assay and Trypan blue exclusion 
test. Apoptosis mechanism was investigated using Annexin V-FITC/PI 
staining and DNA fragmentation assay. Both genes and proteins involved in 
the regulation of cell cycle (p53, p21, CDK1, CDK2, cyclin B1 and cyclin 
E1) and apoptosis (Fas, FADD, Caspase-3, Caspase-8, Caspase-9, Bax, 
Bcl-2, and Cytochrome c) in aloe emodin-treated MCF-7 were determined 
using Quantigene 2.0 Plex and protein ELISA assays respectively. Maximum 
treatment time was set up to 72 hours in all assays. Aloe emodin inhibited the 
proliferation of MCF-7 with IC50 of 80μM. No IC50 value was obtained on 
MDA-MB-231 and MCF-10A, even up to 150μM. In contrast, tamoxifen was 
non-selective to all cells with IC50 of 27μM, 19μM and 42μM, respectively. 
IC50 values obtained were used in all the other assays. Results from Trypan 
blue exclusion test were in concordance with the proliferation assay. Study 
Neuroprotective strategies are required to complement the available medical 
treatments in order to enhance the brain endogenous protective mechanisms 
and cushion the effect of stroke injury. Pharmacological preconditioning 
is an avenue of preventative medication anticipated to be highly effective 
in protecting and reducing the ischemic induced neuronal damage. 
Recently, in vitro preconditioning studies have shown that prior activation 
of group I metabotropic receptor (mGluR) with its specific agonist (S)- 
3,5-dihydroxyphenylglycine ((S)-3,5-DHPG) elicits neuroprotection against
excitotoxicity. Furthermore, the activation of group I mGluR regulates the 
expression of DREAM. DREAM protein regulates transcription of various 
genes including edem1 which is a component protein of ER-associated 
degradation pathway (ERAD). This study elucidates the neuroprotective 
effect of group I mGluR agonist preconditioning, (S)-3,5-DHPG via 
DREAM and ERAD in acute ischemic stroke rats. One, 10 or 100 μM (S)-
3,5-DHPG was administered intrathecally to 6 adult male Sprague Dawley 
rats 2 hours prior to the middle cerebral artery occlusion. After 24 hours, 
the modified neurological severity score (mNSS) and grid walking test 
were assessed. The rats were sacrificed and the infarct brain volumes were 
estimated by 2,3,5-triphenyltetrazolium chloride staining. The serum level 
of neuron-specific enolase (NSE) and brain tissue level of Bip/GRP78 ER 
stress marker were assessed by ELISA assays. The ischemic penumbra tissue 
surrounding the ischemic core infarct was dissected and the cytoplasmic 
on Annexin/PI staining showed the presence of early and late apoptosis 
(18.42% ± 3.53 to 29.25% ± 0.55; p<0.05, n=3 and 28.45% ± 2.36 to 
30.22% ± 0.56; p>0.05, n=3, respectively) in aloe emodin and tamoxifen-
treated MCF-7 cells. Accordingly, DNA fragmentation was observed. Aloe 
emodin and tamoxifen enhanced MCF-7 cytotoxicity through apoptosis. 
In cell cycle signalling, aloe emodin upregulated the expression of p53 
and p21 proteins; while downregulating CDK1. Only CDK1 protein is in 
accordance with gene expression. In intrinsic apoptosis signalling, Bax, 
Cytochrome c and Caspase-9 proteins were upregulated; while no change 
observed in Bcl-2 protein. Except for Caspase-9, these results are in 
accordance with gene expression. In extrinsic apoptosis, Fas and Caspase-8 
were upregulated, contrary to gene expressions. These findings indicate 
that aloe emodin cytotoxic action on MCF-7 cells is through G2/M arrest; 
both extrinsic and intrinsic apoptosis pathways. Its actions on G2/M phase 
arrest and activation of intrinsic apoptosis pathways were p53-dependent, 
while extrinsic apoptosis was p53-independent. Data obtained suggests (i) 
aloe emodin has potential as a selective apoptotic inducer in ER+-breast 
cancer management and (ii) and the present study could be used as a basic 
rationale for in vivo experiment setting.
and nuclear proteins as well as the total RNA were extracted. The protein 
levels of nuclear and cytoplasmic DREAM, as well as EDEM1, SEC61α 
and VCP were analysed by Western blot. The expression of dream and 
edem1 genes were analysed by qRT-PCR. Finally, the level of protein 
degradation activity in the ischemic penumbra tissue was determined by the 
20S proteasomal assay. One or 10 μM of (S)-3,5-DHPG preconditioning 
in stroke rats has significantly improved the neurological functions and 
reduced the brain infarction as well as the NSE level. The DREAM protein 
has significantly increased in the nuclear compartment after 2 hours of 1 
μM (S)-3,5-DHPG administration and in the cytoplasmic compartment 
after 24 hours of 100 μM (S)-3,5- DHPG administration. Similarly, 1 
μM (S)-3,5-DHPG preconditioning has significantly reduced the levels 
of Bip/GRP78 ER stress marker, DREAM and ERAD proteins as well 
as proteasomal degradation activity after 24 hours of an ischemic stroke. 
The expression of dream and edem1 gene were decreased in 1 μM (S)-3,5- 
DHPG preconditioning compared to non-preconditioning ischemic stroke 
rats. In conclusion, the 1 and 10 μM of (S)-3,5-DHPG preconditioning 
enhanced the endogenous protective mechanism via promoting the nuclear 
DREAM protein to regulate the expression of EDEM1 and ERAD activities 
in order to alleviate subsequent ischemic injury in the brain whereas 100 
μM of (S)-3,5-DHPG preconditioning exacerbated the ischemic injury.
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